PMV Pharmaceuticals, Inc.
PMVPAs of the close on Sep 25, 2026
Price
$1.33
Market cap
$71.1M
P/E (diluted TTM)
—
Not meaningful: the last four quarters were a loss
EPS (TTM)
−$1.41
Four quarters to Jun 30, 2026
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How PMV Pharmaceuticals, Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 8 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 5, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Velan Capital Investment Management LP | 2026-03-31 | 73,000 | Not shown | SEC filing |
| Verdad Advisers, LP | 2026-03-31 | 180,161 | Not shown | SEC filing |
| PNC FINANCIAL SERVICES GROUP, INC. | 2026-03-31 | 68,292 | Not shown | SEC filing |
| Tower Research Capital LLC (TRC) | 2026-03-31 | 1,365 | Not shown | SEC filing |
| BOOTHBAY FUND MANAGEMENT, LLC | 2026-03-31 | 27,126 | Not shown | SEC filing |
| JPMORGAN CHASE & CO | 2026-03-31 | 214 | Not shown | SEC filing |
| Corient Private Wealth LLC | 2026-03-31 | 15,000 | Not shown | SEC filing |
| GTS SECURITIES LLC | 2026-03-31 | 10,001 | Not shown | SEC filing |
| Sand Hill Global Advisors, LLC | 2026-03-31 | 12,539 | Not shown | SEC filing |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 2026-03-31 | 19,734 | Not shown | SEC filing |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2026-03-31 | 1,860,000 | Not shown | SEC filing |
| Pathstone Holdings, LLC | 2026-03-31 | 17,487 | Not shown | SEC filing |
| MORGAN STANLEY | 2026-03-31 | 864,311 | Not shown | SEC filing |
| BIT Capital GmbH | 2026-03-31 | 123,555 | Not shown | SEC filing |
| JANE STREET GROUP, LLC | 2026-03-31 | 124,014 | Not shown | SEC filing |
| BANK OF AMERICA CORP /DE/ | 2026-03-31 | 240,531 | Not shown | SEC filing |
| Point72 Asset Management, L.P. | 2026-03-31 | 20,945 | Not shown | SEC filing |
| BNP PARIBAS FINANCIAL MARKETS | 2026-03-31 | 539 | Not shown | SEC filing |
| ROYAL BANK OF CANADA | 2026-03-31 | 904 | Not shown | SEC filing |
| Accurate Wealth Management, LLC | 2026-03-31 | 50,000 | Not shown | SEC filing |
- Each value is checked against PMV Pharmaceuticals, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 20 rows: no share price from within three months of their report dates is on file, so they could not be checked.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- Walleye Capital LLC: 335,694 shares reported 2025-12-31; 335,694 shares reported 2026-03-31.
- CITADEL ADVISORS LLC: 118,593 shares reported 2025-12-31; 45,048 shares reported 2026-03-31.
- Quadrature Capital Ltd: 18,428 shares reported 2025-12-31; 61,174 shares reported 2026-03-31.
- ACADIAN ASSET MANAGEMENT LLC: 2,015,770 shares reported 2025-12-31; 2,215,894 shares reported 2026-03-31.
- BARCLAYS PLC: 27,536 shares reported 2025-12-31; 27,536 shares reported 2026-03-31.
- STATE STREET CORP: 183,178 shares reported 2025-12-31; 183,178 shares reported 2026-03-31.
- Euclidean Capital LLC: 2,627,643 shares reported 2025-12-31; 2,627,643 shares reported 2026-03-31.
- Rangeley Capital, LLC: 45,500 shares reported 2025-12-31; 66,846 shares reported 2026-03-31.
- ALGERT GLOBAL LLC: 62,020 shares reported 2025-12-31; 41,590 shares reported 2026-03-31.
- TWO SIGMA INVESTMENTS, LP: 706,061 shares reported 2025-12-31; 1,884,530 shares reported 2026-03-31.
- BRIDGEWAY CAPITAL MANAGEMENT, LLC: 428,853 shares reported 2025-12-31; 428,853 shares reported 2026-03-31.
- HSBC HOLDINGS PLC: 30,891 shares reported 2025-12-31; 30,891 shares reported 2026-03-31.
Showing the 12 most recent filer reports.
31 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among PMV Pharmaceuticals, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-10-23 · ORBIMED ADVISORS LLC: Larger than all 113 other insider sales of Common Stock on file. SEC filing
- 2025-09-10 · ORBIMED ADVISORS LLC: Larger than 112 of the 113 other insider sales of Common Stock on file. SEC filing
- 2025-07-01 · Jalota Deepika: Larger than 104 of the 113 other insider sales of Common Stock on file. SEC filing
- 2025-07-01 · Mack David Henry: Larger than 108 of the 113 other insider sales of Common Stock on file. SEC filing
- 2023-11-22 · ORBIMED ADVISORS LLC: Larger than 110 of the 113 other insider sales of Common Stock on file. SEC filing
- 2022-03-31 · ORBIMED ADVISORS LLC: Larger than 106 of the 113 other insider sales of Common Stock on file. SEC filing
- 2022-03-30 · ORBIMED ADVISORS LLC: Larger than 109 of the 113 other insider sales of Common Stock on file. SEC filing
- 2022-03-29 · ORBIMED ADVISORS LLC: Larger than 111 of the 113 other insider sales of Common Stock on file. SEC filing
- 2021-09-10 · Schroeder Thilo: Larger than 107 of the 113 other insider sales of Common Stock on file. SEC filing
- 2021-08-11 · Schroeder Thilo: Larger than 105 of the 113 other insider sales of Common Stock on file. SEC filing
- 2021-08-04 · Schroeder Thilo: Larger than 102 of the 113 other insider sales of Common Stock on file. SEC filing
- 2021-08-03 · Schroeder Thilo: Larger than 103 of the 113 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2025-10-23 | ORBIMED ADVISORS LLC · 10% owner | Common Stock | S — Open market or private sale | −1,000,000 | 1.52 | SEC filing |
| 2025-09-10 | ORBIMED ADVISORS LLC · 10% owner | Common Stock | S — Open market or private sale | −500,000 | 1.80 | SEC filing |
| 2025-07-01 | Mack David Henry · President and CEO | Common Stock | S — Open market or private sale | −58,411 | 1.06 | SEC filing |
| 2025-07-01 | Carulli Michael · Chief Financial Officer | Common Stock | S — Open market or private sale | −28,249 | 1.06 | SEC filing |
| 2025-07-01 | Ticktin Robert · General Counsel & COO | Common Stock | S — Open market or private sale | −23,151 | 1.06 | SEC filing |
| 2025-07-01 | Jalota Deepika · Chief Development Officer | Common Stock | S — Open market or private sale | −33,065 | 1.06 | SEC filing |
| 2024-09-11 | Carulli Michael · Chief Financial Officer | Common Stock | S — Open market or private sale | −2,891 | 1.50 | SEC filing |
| 2024-09-11 | Jalota Deepika · Chief Development Officer | Common Stock | S — Open market or private sale | −7,218 | 1.50 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-04 | Gallagher Carol Giltner · Director | Stock Option (right to buy) | G — Bona fide gift | −42,000 | SEC filing |
| 2026-06-04 | Gallagher Carol Giltner · Director | Stock Option (right to buy) | G — Bona fide gift | +42,000 | SEC filing |
| 2026-06-04 | FLOWERS KIRSTEN · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +42,000 | SEC filing |
| 2026-06-04 | Gallagher Carol Giltner · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +42,000 | SEC filing |
| 2026-06-04 | BAUM CHARLES M · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +42,000 | SEC filing |
| 2026-06-04 | LEVINE ARNOLD J · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +42,000 | SEC filing |
| 2026-06-04 | Stelzer Laurie · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +42,000 | SEC filing |
| 2026-03-05 | Ticktin Robert · General Counsel & COO | Employee Stock Option (right to buy) | A — Grant, award, or other acquisition | +319,270 | SEC filing |
Showing 8 of 30 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2024-08-13 | Mack David Henry · President and CEO | Employee Stock Option (right to buy) | D — Disposition to the issuer | −249,600 | SEC filing |
| 2024-08-13 | Carulli Michael · Chief Financial Officer | Employee Stock Option (right to buy) | D — Disposition to the issuer | −27,200 | SEC filing |
| 2024-08-13 | Carulli Michael · Chief Financial Officer | Employee Stock Option (right to buy) | D — Disposition to the issuer | −13,605 | SEC filing |
| 2024-08-13 | Jalota Deepika · Chief Development Officer | Employee Stock Option (right to buy) | D — Disposition to the issuer | −125,000 | SEC filing |
| 2024-08-13 | Jalota Deepika · Chief Development Officer | Employee Stock Option (right to buy) | D — Disposition to the issuer | −22,674 | SEC filing |
| 2024-08-13 | Carulli Michael · Chief Financial Officer | Employee Stock Option (right to buy) | D — Disposition to the issuer | −75,000 | SEC filing |
| 2024-08-13 | Mack David Henry · President and CEO | Employee Stock Option (right to buy) | D — Disposition to the issuer | −134,584 | SEC filing |
| 2024-08-13 | Mack David Henry · President and CEO | Employee Stock Option (right to buy) | D — Disposition to the issuer | −330,000 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.